Clinical Trial Update: Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating famitinib in combination with camrelizumab and TPC as first-line treatment for immunomodulatory locally advanced or metastatic triple-n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Famitinib (Famitinib)
• TPC

Snippet

Sponsor: Fudan University | Conditions: Triple-Negative Breast Cancer | Phase 3 | Status: RECRUITING